When was Mithradote Bio founded?

Mithradote Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.

Where is Mithradote Bio located?

Mithradote Bio is headquartered in San Diego, United States.

Who is the current CEO of Mithradote Bio?

Sophia Lee of Mithradote Bio. They have also founded 1 company.

Is Mithradote Bio a funded company?

Mithradote Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Oct 02, 2024.

When was the latest funding round of Mithradote Bio?

Mithradote Bio's latest funding was a $***** Seed round on Oct 02, 2024, with participation from 2 investors.

Where does Mithradote Bio rank among its competitors?

Mithradote Bio ranks 7th amongst 20 active competitors, of which 6 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Ensysce, which secured $4M in Nov, 2025.

Who are the top competitors of Mithradote Bio?

Mithradote Bio's top competitors include Ensysce, IgGenix and Tempero Bio. Among them, Ensysce secured the most recent funding round in November, 2025.

Mithradote Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of medication to help prevent drug-facilitated sexual assault. It offers a lead product, M-101, a novel sublingual pan-antidote against benzodiazepines, Z drugs, and other GABA agonists.

Key Metrics

Founded Year

2023

Location

San Diego, United States

Stage

Seed

Total Funding

$1M in 1 round

Latest Funding Round

Seed, Oct 02, 2024, $*****

Investors

Vickers Venture Partners & 1 more

Ranked

7^th among 20 active competitors

Similar Companies

Ensysce & 20 more

View Mithradote Bio's full profile

Mithradote Bio has raised a total funding of $1M over 1 round. Its latest funding round was a Seed round on Oct 02, 2024 for $*****. 2 investors participated in its latest round. Mithradote Bio has 2 institutional investors.

Here is the list of recent funding rounds of Mithradote Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 02, 2024	9158078	Seed	3989884	9266176	5072529	2537959

Access funding benchmarks and valuations. Sign up today!

View details of Mithradote Bio's funding rounds and investors

The founders of Mithradote Bio is Sophia Lee. Sophia Lee is the CEO of Mithradote Bio.

Here are the details of Mithradote Bio's key team members:

Sophia Lee: Founder & CEO of Mithradote Bio.
Contact Info: 1 email address

View details of Mithradote Bio's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mithradote Bio include Ensysce, IgGenix and Tempero Bio. Here is the list of Top 10 competitors of Mithradote Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ensysce 2008, Houston (United States), Public	Provider of drug delivery problems with Single-Walled Carbon Nanotubes	$2.5M	SBIR, Texas Emerging Technology Fund & 1 others	53/100
2nd	IgGenix 2019, San Francisco (United States), Series B	Developer of therapeutic solutions for treating food allergy	$75M	Khosla Ventures, Alexandria & 7 others	51/100
3rd	Tempero Bio 2020, Oakland (United States), Series B	Developer of therapeutics to treat opioid use disorders	$77M	8VC, Khosla Ventures & 1 others	48/100
4th	ALAR 2016, Taichung (Taiwan), Public	Developer of drugs for opioid use disorder and depressive disorder	-	-	37/100
5th	OVAX 2023, Houston (United States), Unfunded	Developer of vaccine that prevents fentanyl from entering the brain	-	-	32/100
6th	Sobrera 2019, Gothenburg (Sweden), Funding Raised	Developer of drugs for treating alcohol use disorders	-	Byggmastare Anders J Ahlstrom Holding, GU Ventures ... & 3 others	31/100
7th	Mithradote Bio 2023, San Diego (United States), Seed	Provider of medication to help prevent drug-facilitated sexual assault	$1M	Vickers Venture Partners, Taho Pharma	31/100
8th	Globin Solutions 2017, Pittsburgh (United States), Series A	Developer of antidotal therapies for human poisonings	$5M	Tuspark, UPMC & 1 others	31/100
9th	D&A Pharma 2006, Houdan (France), Unfunded	Developer of therapeutics for the treatment of rare diseases	-	-	27/100
10th	Xatca 2018, Victoria (Canada), Unfunded	Developer of therapeutics for addiction disorders	-	-	24/100